28232171|t|Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures
28232171|a|Dopamine is an immunomodulatory molecule that acts on immune effector cells both in the CNS and peripheral tissues. However, the role of changes in dopamine levels in the neuroinflammatory response is controversial. The local/ paracrine renin-angiotensin system (RAS) plays a major role in inflammatory processes in peripheral tissues and brain. In the present study, we investigated the possible role of the brain RAS in the effects of dopamine on the glial inflammatory responses. Astrocytes are the major source of the precursor protein angiotensinogen and angiotensin II (AII) in the brain. Neurotoxins such as MPP (+) (1-methyl-4-phenylpyridinium) can act directly on astrocytes to increase levels of angiotensinogen and AII. Conversely, dopamine, via type-2 (D2) receptors, inhibited production of angiotensinogen, decreased expression of angiotensin type-1 (AT1) receptors and increased expression of AT2 receptors. In microglia, dopamine and dopamine agonists also regulated RAS activity. First, indirectly, via downregulation of the astrocyte-derived AII. Second, via dopamine - induced regulation of microglial angiotensin receptors. Dopamine decreased the microglial AT1 / AT2 ratio leading to inhibition of the pro-inflammatory AT1 / NADPH-oxidase / superoxide axis. D2 receptors were particularly responsible for microglial RAS inhibition in basal culture conditions. However, both D1 and D2 agonists inhibited the AT1 / NADPH-oxidase axis in lipopolysaccharide - treated (LPS; i.e. activated) microglia. The results indicate that the decrease in dopamine levels observed in early stages of Parkinson's disease and aging may promote neuroinflammation and disease progression via glial RAS exacerbation.
28232171	0	8	Dopamine	T109,T121,T123	C0013030
28232171	9	18	modulates	T082	C0443264
28232171	19	29	astroglial	T025	C0004112
28232171	34	44	microglial	T025	C0206116
28232171	45	53	activity	T043	C0007613
28232171	58	63	glial	T025	C0027836
28232171	64	88	renin-angiotensin system	T022	C0035096
28232171	92	100	cultures	T059	C0040284
28232171	101	109	Dopamine	T109,T121,T123	C0013030
28232171	116	141	immunomodulatory molecule	T121,T129	C1527392
28232171	147	151	acts	T052	C3266814
28232171	155	176	immune effector cells	T025	C0312740
28232171	189	192	CNS	T022	C3714787
28232171	197	207	peripheral	T082	C0205100
28232171	208	215	tissues	T024	C0040300
28232171	238	245	changes	T169	C0392747
28232171	249	264	dopamine levels	T059	C0201989
28232171	272	289	neuroinflammatory	T169	C0333348
28232171	290	298	response	T032	C0871261
28232171	302	315	controversial	T054	C0680243
28232171	328	337	paracrine	T039	C0597170
28232171	338	362	renin-angiotensin system	T022	C0035096
28232171	364	367	RAS	T022	C0035096
28232171	391	413	inflammatory processes	T046	C1155266
28232171	417	427	peripheral	T082	C0205100
28232171	428	435	tissues	T024	C0040300
28232171	440	445	brain	T023	C0006104
28232171	462	467	study	T062	C0008972
28232171	472	484	investigated	T169	C1292732
28232171	510	515	brain	T023	C0006104
28232171	516	519	RAS	T022	C0035096
28232171	527	534	effects	T080	C1280500
28232171	538	546	dopamine	T109,T121,T123	C0013030
28232171	554	559	glial	T025	C0027836
28232171	560	582	inflammatory responses	T046	C1155266
28232171	584	594	Astrocytes	T025	C0004112
28232171	623	640	precursor protein	T116,T123	C0033665
28232171	641	656	angiotensinogen	T116,T123	C0003017
28232171	661	675	angiotensin II	T116,T121,T123	C0003009
28232171	677	680	AII	T116,T121,T123	C0003009
28232171	689	694	brain	T023	C0006104
28232171	696	707	Neurotoxins	T131	C0027934
28232171	716	719	MPP	T109,T131	C0000098
28232171	725	752	1-methyl-4-phenylpyridinium	T109,T131	C0000098
28232171	758	761	act	T052	C3266814
28232171	762	770	directly	T080	C1947931
28232171	774	784	astrocytes	T025	C0004112
28232171	788	796	increase	T081	C0205217
28232171	797	803	levels	T080	C0441889
28232171	807	822	angiotensinogen	T116,T123	C0003017
28232171	827	830	AII	T116,T121,T123	C0003009
28232171	844	852	dopamine	T109,T121,T123	C0013030
28232171	858	879	type-2 (D2) receptors	T116,T192	C0058698
28232171	881	890	inhibited	T052	C3463820
28232171	891	901	production	T044	C0597295
28232171	905	920	angiotensinogen	T116,T123	C0003017
28232171	922	931	decreased	T080	C0392756
28232171	932	942	expression	T045	C1171362
28232171	946	980	angiotensin type-1 (AT1) receptors	T116,T192	C0529330
28232171	985	994	increased	T081	C0205217
28232171	995	1005	expression	T045	C1171362
28232171	1009	1022	AT2 receptors	T116,T192	C0390423
28232171	1027	1036	microglia	T025	C0206116
28232171	1038	1046	dopamine	T109,T121,T123	C0013030
28232171	1051	1068	dopamine agonists	T121	C0178601
28232171	1074	1083	regulated	T038	C1327622
28232171	1084	1087	RAS	T022	C0035096
28232171	1088	1096	activity	T052	C0441655
28232171	1105	1115	indirectly	T080	C0439852
28232171	1121	1135	downregulation	T044	C0013081
28232171	1143	1164	astrocyte-derived AII	T116,T121,T123	C0003009
28232171	1178	1186	dopamine	T109,T121,T123	C0013030
28232171	1189	1196	induced	T169	C0205263
28232171	1197	1207	regulation	T038	C1327622
28232171	1211	1221	microglial	T025	C0206116
28232171	1222	1243	angiotensin receptors	T116,T192	C0034787
28232171	1245	1253	Dopamine	T109,T121,T123	C0013030
28232171	1254	1263	decreased	T080	C0392756
28232171	1268	1278	microglial	T025	C0206116
28232171	1279	1282	AT1	T116,T192	C0529330
28232171	1285	1288	AT2	T116,T192	C0390423
28232171	1289	1294	ratio	T081	C0456603
28232171	1306	1316	inhibition	T052	C3463820
28232171	1324	1344	pro-inflammatory AT1	T116,T192	C0529330
28232171	1347	1360	NADPH-oxidase	T116,T126	C0068355
28232171	1363	1373	superoxide	T196	C0038836
28232171	1374	1378	axis	T082	C1522496
28232171	1380	1392	D2 receptors	T116,T192	C0058698
28232171	1427	1437	microglial	T025	C0206116
28232171	1438	1441	RAS	T022	C0035096
28232171	1442	1452	inhibition	T052	C3463820
28232171	1456	1461	basal	T082	C0205112
28232171	1462	1469	culture	T059	C0040284
28232171	1470	1480	conditions	T080	C0348080
28232171	1496	1498	D1	T121	C0178601
28232171	1503	1514	D2 agonists	T121	C0178601
28232171	1515	1524	inhibited	T052	C3463820
28232171	1529	1532	AT1	T116,T192	C0529330
28232171	1535	1548	NADPH-oxidase	T116,T126	C0068355
28232171	1549	1553	axis	T082	C1522496
28232171	1557	1575	lipopolysaccharide	T109	C0023810
28232171	1578	1585	treated	T052	C1879547
28232171	1587	1590	LPS	T109	C0023810
28232171	1597	1606	activated	T052	C1879547
28232171	1608	1617	microglia	T025	C0206116
28232171	1623	1630	results	T169	C1274040
28232171	1649	1657	decrease	T080	C0392756
28232171	1661	1676	dopamine levels	T059	C0201989
28232171	1689	1701	early stages	T079	C2363430
28232171	1705	1724	Parkinson's disease	T047	C0030567
28232171	1729	1734	aging	T040	C0001811
28232171	1739	1746	promote	T052	C0033414
28232171	1747	1764	neuroinflammation	T046	C0021368
28232171	1769	1788	disease progression	T046	C0242656
28232171	1793	1798	glial	T025	C0027836
28232171	1799	1802	RAS	T022	C0035096
28232171	1803	1815	exacerbation	T033	C4086268